Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer

NCT00387907 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Breast Cancer
Breast Cancer
Metastatic Breast Cancer

Interventions

DRUG: larotaxel (XRP9881)
DRUG: trastuzumab

Sponsor

Sanofi